Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization

Table 3 Univariate and multivariate analysis

Variables1	LLC (n = 38)			DLC (n = 34)			DM (n = 31)			PFS (n = 34)			OS (n = 34)
	UVA (P)	MVA (P)	HR (95%CI)	UVA (P)	MVA (P)	HR (95%CI)	UVA (P)	MVA (P)	HR (95%CI)	UVA (P)	MVA (P)	HR (95%CI)	UVA (P)	MVA (P)	HR (95%CI)
FDG Avidity (avid vs non-avid)	0.003	0.002	6.3 (2.0-20.4)	0.003	0.015	57.7 (2.2-1496.9)	< 0.001	NS		0.015	0.008	4.04 (1.4-11.3)	0.893	-
ECOG (0 vs 1 vs≥ 2)	0.120	-		0.038	NS		0.990	-		0.049	NS		0.002	NS
Gender (female vs male)	0.100	NS		0.398	-		0.596	-		0.100	NS		0.122	-
Pathology (grade 1 vs 2 vs 3 vs unknown)	0.059	NS		0.034	NS		0.048	NS		0.016	NS		0.688	-
Extrahepatic disease	< 0.001	< 0.001	38.9 (6.6-229.2)	< 0.001	NS		-	-		< 0.001	< 0.001	47 (7.7-286)	< 0.001	NS
Tumor Burden ( ≤ 50% vs > 50%)	< 0.001	NS		0.009	NS		0.990	-		0.012	NS		0.004	NS
Cirrhosis	0.477	-		0.588	-		0.732	-		0.593	-		0.065	NS
Age (yr)	0.405	-		0.405	-		0.238	-		0.232	-		0.100	NS

¹Variables tested but not significant for outcome on univariate analysis (UVA) includes: Portal vein thrombosis, prior treatment, Child-Pugh class (A vs B), viral hepatitis, initial AFP, volume treated and dose delivered. ECOG: Eastern Cooperative Oncology Group Performance Status; LLC: Local liver control; DLC: Distant liver control; DM: Distant metastases; PFS: Progression free survival; OS: Overall survival.